Soluble urokinase plasminogen activator receptor level in individuals of advanced age

Abstract

Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker whose clinical value has been tested in various groups of patients. The aim of the present study was to determine the suPAR level in a previously uninvestigated population of 182, generally healthy, community-dwelling seniors aged 74–89 years. In addition to suPAR level, selected laboratory parameters of heart and kidney function, lipid and C-reactive protein levels were determined. A group of 45 younger individuals aged 24–66 years was used for comparison. The seniors had higher suPAR levels than younger controls: 3.79 ng/mL (95% CI 3.64–3.96 ng/mL) vs. 3.16 ng/mL (95% CI 2.86–3.45 ng/mL). These levels increased further with advancing age, and were similar in women and men. A multiple regression model confirmed that biomarker level was related to cardiac function, renal function and inflammation, and this remained after adjusting for age. These correlation patterns were similar in older women and men.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

“…In blood donors, the median suPAR level is around 2 ng/mL ( 25 ), and women generally have slightly higher suPAR than men ( 25 – 27 ). However, suPAR seems to increase more with age in men compared to women, and suPAR is similar among men and women in older adults (≥74 years of age) ( 28 ). suPAR concentrations are higher in serum than in plasma within individuals ( 27 , 29 ).…”

The predictive value of modified soluble urokinase plasminogen activator receptor (suPAR) with National Early Warning Score (NEWS) for mortality in emergency elderly patients in Japan: a prospective pilot study

“…In a study carried by Rafal et al ., 23 the suPAR level of elderly people was higher than that of younger people. In this study, however, there was no significant difference in age between the survivor's group and the nonsurvivors group, and therefore we assumed that the age between the two groups had no effect on the suPAR level.…”

“…In our study, we included eight cases of nonsurvivors and 39 survivors based on the sample size test, and the AUC of suPAR for mortality was 0.805, which was almost the same as the set value of 0.8. In a study carried by Rafal et al, 23 the suPAR level of elderly people was higher than that of younger people. In this study, however, there was no significant difference in age between the survivor's group and the nonsurvivors group, and therefore we assumed that the age between the two groups had no effect on the suPAR level.…”

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients

“…The plasma concentration of suPAR increases in both acute and chronic inflammatory states such as infectious diseases, sepsis, autoimmune diseases, malignancies, cardiovascular diseases and organ dysfunctions such as liver and kidney failure, when, in contrast, stays rather low in primary healthy individuals [ 12 , 13 , 14 ]. Furthermore, suPAR values in the general population increase with advancing age: a former study suggests that patients aged 74–89 years had significantly higher suPAR values than individuals between 24–66 years [ 15 ].…”